NCT03415282View on ClinicalTrials.gov

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

July 24, 2018

Study Completion Date

August 7, 2018

Conditions
Atopic Dermatitis
Interventions
DRUG

RVT-501 0.5% topical ointment

RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.

Trial Locations (12)

23220

Dermavant Investigational Site, Richmond

27612

Dermavant Investigational Site, Raleigh

30281

Dermavant Investigational Site, Stockbridge

32256

Dermavant Investigational Site, Jacksonville

33172

Dermavant Investigational Site, Miami

33174

Dermavant Investigational Site, Miami

36207

Dermavant Investigational Site, Anniston

46256

Dermavant Investigational Site, Indianapolis

76011

Dermavant Investigational Site, Arlington

78213

Dermavant Investigational Site, San Antonio

78229

Dermavant Investigational Site, San Antonio

92617

Dermavant Investigational Site, Irvine

Sponsors
All Listed Sponsors
lead

Dermavant Sciences GmbH

INDUSTRY

NCT03415282 - Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter